STOCK TITAN

Schrödinger to Participate in Five Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate virtually at the following investor conferences:

  • 33rd Annual Piper Sandler Virtual Healthcare Conference: A pre-recorded fireside chat will be available today after 10:00 a.m. ET.
  • 4th Annual Evercore ISI HealthCONx Conference: Management will participate in a fireside chat on Tuesday, November 30, 2021, at 4:20 p.m. ET.
  • BMO 2021 Growth & ESG Conference: A fireside chat will take place on Tuesday, December 7th at 1:00 p.m. ET.
  • Goldman Sachs Byte-ology: The Convergence of Biotechnology and Technology: A Biotech panel will take place on Thursday, December 9, 2021, at 10:00 a.m. ET.

Additionally, the company will participate in one-on-one meetings during the Berenberg Discover AI Seminar 2021 on Wednesday, December 1st.

The live and pre-recorded webcasts can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, our blog www.extrapolations.com, or follow us on LinkedIn and Twitter.

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com

617-286-6264

Tracy Lessor

Schrödinger, Inc.

tracy.lessor@schrodinger.com

617-519-9827

Source: Schrödinger

Schrödinger, Inc.

NASDAQ:SDGR

SDGR Rankings

SDGR Latest News

SDGR Stock Data

1.65B
61.36M
2.42%
92.55%
8.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About SDGR

schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part